Pre-made Adecatumumab benchmark antibody (Whole mAb, anti-EPCAM therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) for drug discovery and mechanism of action (MOA) research

Anti-EPCAM therapeutic antibody (Pre-made Adecatumumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Adecatumumab (MT21) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-719-1mg	1mg	3090
GMP-Bios-INN-719-10mg	10mg	Inquiry
GMP-Bios-INN-719-100mg	100mg	Inquiry
GMP-Bios-INN-719-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Adecatumumab Biosimilar, Whole Mab, Anti-Epcam Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody
INN Name	Adecatumumab
Target	EPCAM
Format	Whole mAb
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG1 - nd
VD LC	IgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Micromet AG (Munich Germany)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Human antibody phage display library